other material
confidence high
sentiment neutral
materiality 0.65
Protalix increases ATM equity offering capacity by $20M for general corporate purposes
Protalix BioTherapeutics, Inc.
- Amendment with H.C. Wainwright increases ATM offering capacity by $20M in aggregate gross sales price.
- Net proceeds will be used for general corporate purposes, including working capital and clinical trials.
- Prospectus supplement filed to register additional shares under existing shelf registration statement.
- No shares were previously available for sale under the existing Sales Agreement.